Pictet Asset Management (Switzerland)’s Enanta Pharmaceuticals ENTA Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$8.42M	Buy	393,399 +122,546	+45%	+$3.61M	0.01%	656
2023 Q1	$11M	Buy	270,853 +197,916	+271%	+$9.45M	0.01%	601
2022 Q4	$3.39M	Buy	72,937 +18,840	+35%	+$859K	﹤0.01%	829
2022 Q3	$2.81M	Buy	54,097 +24,468	+83%	+$1.43M	﹤0.01%	853
2022 Q2	$1.4M	Buy	+29,629	New	+$1.61M	﹤0.01%	996

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ENTA Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Enanta Pharmaceuticals (ENTA) stake by 45% in Q2 2023, buying an estimated $3.61M and bringing the position to 393,399 shares worth $8.42M. The position accounts for 0.01% of the portfolio, ranked #656.

Pictet Asset Management (Switzerland) first reported a position in ENTA in Q2 2022 and has held it in 5 quarters since. The position peaked at $11M in Q1 2023. 134 funds tracked by Wall St. Rank hold ENTA as of Q2 2023.

Pictet Asset Management (Switzerland) held 393,399 shares of Enanta Pharmaceuticals worth $8.42M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 122,546 Enanta Pharmaceuticals shares in Q2 2023, an estimated $3.61M.
Enanta Pharmaceuticals made up 0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #656 holding.
Pictet Asset Management (Switzerland) first reported a position in Enanta Pharmaceuticals in Q2 2022 and has held it in 5 quarters since.
Pictet Asset Management (Switzerland)'s Enanta Pharmaceuticals position peaked at $11M in Q1 2023.
134 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.